A Randomized, Vehicle Controlled, Active Comparator, Parallel Group Study to Evaluate Efficacy, Safety, and Tolerability of Topical LFX453 Formulations in Patients With External Genital Warts (EGWs) is a PHASE2 clinical asset sponsored by Novartis Pharmaceuticals in External Genital Warts. SEO and diligence focus: Investigational Treatment, Aldara, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.